Cargando…
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
Immunogenicity, defined as the ability to provoke an immune response, can be either wanted (i.e., vaccines) or unwanted. The latter refers to an immune response to protein or peptide therapeutics, characterized by the production of anti-drug antibodies, which may affect the efficacy and/or the safet...
Autores principales: | Siegel, Michel, Steiner, Guido, Franssen, Linnea C., Carratu, Francesca, Herron, James, Hartman, Katharina, Looney, Cary M., Ducret, Axel, Bray-French, Katharine, Rohr, Olivier, Hickling, Timothy P., Smith, Noel, Marban-Doran, Céline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781343/ https://www.ncbi.nlm.nih.gov/pubmed/36559166 http://dx.doi.org/10.3390/pharmaceutics14122672 |
Ejemplares similares
-
Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes
por: Hartman, Katharina, et al.
Publicado: (2023) -
Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016) -
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
por: Kuriakose, Anshu, et al.
Publicado: (2016) -
Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
por: Bivi, Nicoletta, et al.
Publicado: (2019) -
Restimulating Interest in Cytomegalovirus as a Cofactor for HIV Infection
por: Emery, Vincent C.
Publicado: (2015)